Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference

Stock Information for VolitionRX Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About VolitionRX Limited

VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update
VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium
Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients
VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update
Volition Announces Detection of Over 95% of Early-Stage Cancers
Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA
Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.